211 related articles for article (PubMed ID: 34671700)
1. Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.
Parikh NR; Clark MA; Patel P; Kafka-Peterson K; Zaide L; Ma TM; Steinberg ML; Cao M; Raldow AC; Lamb J; Kishan AU
Appl Radiat Oncol; 2021 Sep; 10(3):33-40. PubMed ID: 34671700
[TBL] [Abstract][Full Text] [Related]
2. Time-Driven Activity-Based Costing Comparison of CT-Guided Versus MR-Guided SBRT.
Parikh NR; Lee PP; Raman SS; Cao M; Lamb J; Tyran M; Chin W; Gilchrist T; Agazaryan N; Mittauer K; Steinberg ML; Raldow AC
JCO Oncol Pract; 2020 Nov; 16(11):e1378-e1385. PubMed ID: 32539652
[TBL] [Abstract][Full Text] [Related]
3. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
[TBL] [Abstract][Full Text] [Related]
4. Optimization of treatment workflow for 0.35T MR-Linac system.
Behzadipour M; Palta J; Ma T; Yuan L; Kim S; Kirby S; Torkelson L; Baker J; Koenig T; Khalifa MA; Hawranko R; Richeson D; Fields E; Weiss E; Song WY
J Appl Clin Med Phys; 2024 May; ():e14393. PubMed ID: 38742819
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
9. Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer.
Tetar SU; Bruynzeel AME; Lagerwaard FJ; Slotman BJ; Bohoudi O; Palacios MA
Phys Imaging Radiat Oncol; 2019 Jan; 9():69-76. PubMed ID: 33458428
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.
Ugurluer G; Atalar B; Zoto Mustafayev T; Gungor G; Aydin G; Sengoz M; Abacioglu U; Tuna MB; Kural AR; Ozyar E
Br J Radiol; 2021 Jan; 94(1117):20200696. PubMed ID: 33095670
[TBL] [Abstract][Full Text] [Related]
11. Biologically Equivalent Dose Comparison Between Magnetic Resonance-Guided Adaptive and Computed Tomography-Guided Internal Target Volume-Based Stereotactic Body Radiotherapy for Liver Tumors.
Yoda K; Sato A; Miyake Y; Arato T; Starbuck W
Cureus; 2023 Jan; 15(1):e33478. PubMed ID: 36756023
[TBL] [Abstract][Full Text] [Related]
12. Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results.
Sandoval ML; Youssef I; Latifi K; Grass GD; Torres-Roca J; Rosenberg S; Yamoah K; Johnstone PA
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362179
[TBL] [Abstract][Full Text] [Related]
13. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
Leeman JE; Shin KY; Chen YH; Mak RH; Nguyen PL; D'Amico AV; Martin NE
Cancer; 2023 Oct; 129(19):3044-3052. PubMed ID: 37485697
[TBL] [Abstract][Full Text] [Related]
14. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors.
Padgett KR; Simpson GN; Llorente R; Samuels MA; Dogan N
Cureus; 2018 Apr; 10(4):e2423. PubMed ID: 29872603
[TBL] [Abstract][Full Text] [Related]
16. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
Chuong MD; Clark MA; Henke LE; Kishan AU; Portelance L; Parikh PJ; Bassetti MF; Nagar H; Rosenberg SA; Mehta MP; Refaat T; Rineer JM; Smith A; Seung S; Zaki BI; Fuss M; Mak RH
Clin Transl Radiat Oncol; 2023 Jan; 38():161-168. PubMed ID: 36466748
[TBL] [Abstract][Full Text] [Related]
17. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric study for spine stereotactic body radiation therapy: magnetic resonance guided linear accelerator versus volumetric modulated arc therapy.
Yadav P; Musunuru HB; Witt JS; Bassetti M; Bayouth J; Baschnagel AM
Radiol Oncol; 2019 Sep; 53(3):362-368. PubMed ID: 31553704
[TBL] [Abstract][Full Text] [Related]
19. Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability.
Nicosia L; Mazzola R; Rigo M; Giaj-Levra N; Pastorello E; Ricchetti F; Vitale C; Figlia V; Cuccia F; Ruggieri R; Alongi F
Radiol Med; 2023 May; 128(5):612-618. PubMed ID: 37055672
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
